Strategic positioning Position Foghorn Therapeutics as a partner for pharma companies seeking novel chromatin-targeted therapies by highlighting their Gene Traffic Control platform and deep mechanistic understanding of chromatin regulation to enable targeted discovery collaborations and co-development opportunities.

Clinical collaboration Leverage recent preclinical data on SMARCA2, CBP/EP300, and ARID1B degraders to propose joint research programs or licensing deals with biotech and large-cap players pursuing chromatin remodeler targets and synthetic lethality strategies.

Commercial expansion Capitalize on geographic and office expansion to Massachusetts by offering contract research, sponsored programs, or regional partnerships with biotech clusters in Watertown/Cambridge to shorten collaboration timelines and access local talent.

Financially resolute Utilize the current funding and revenue profile to support value-forward partnerships, offering milestone-driven deals and upfronts aligned with scale-up of preclinical programs, while presenting a clear ROI path for potential licensees.

Industry engagement Target participation opportunities in major biotech conferences and investor events (e.g., AACR, Guggenheim Biotech Summit) to generate visibility for pipeline programs, identify potential strategic investors, and unlock partnering conversations with peers progressing chromatin-targeted therapies.